Ambit Partners with Datavant to Drive Innovation in the Rare and Specialty Disease Markets 

Rare Daily Staff

Ambit, an integrated biopharma solutions firm specializing in the rare and specialty disease markets, has partnered with Datavant to accelerate data-driven innovation for biopharma companies.​​

“Our partnership with Datavant will enable us to unlock the power of comprehensive, de-identified data from diverse sources, including claims, electronic health records, diagnostic tests, and demographic information,” said Jonathan Woodring, chief innovation officer at Ambit. “By combining this data with our advanced analytics methods, such as artificial intelligence and machine learning, we can provide unparalleled market insights and identify​​ patients who may have been undiagnosed or misdiagnosed.”​​​​​​

​​​​​​​Ambit’s mission is to provide best-in-class advanced analytics and innovative technology solutions to the most complex challenges facing biopharma companies. With this new partnership, Ambit aims to further enhance its capabilities by leveraging Datavant’s expansive​ network of real-world data partners​ and expertise in ​secure data connectivity.​

Datavant powers the nation’s largest health data ecosystem​ encompassing ​more than ​2,200 hospitals, 15,000 clinics, 35 life sciences organizations, ​120 health plans​, ​and 500 real-world data partners across life sciences, public sector, and data and analytics organizations.​​ ​​Datavant’s suite of data connectivity tools enables organizations to link disparate datasets compliantly and securely, in order to unlock health insights to improve patient outcomes while protecting patient privacy. ​

By ​joining the Datavant Ecosystem, Ambit​ ​will be able to link its ​proprietary data sources​ with various types of real-world data,​ ​advancing its analytics capabilities​ and enabling the development of​​ a range of innovative products and services so biopharma clients can gain deeper insights into patient journeys, understand market dynamics, and effectively identify rare disease patients who may require specialized treatments.

“It’s imperative that we break down the data silos that stifle innovation and impede patient understanding, and with each partner that joins the Datavant Ecosystem, we come closer to achieving our collective mission to improve patient outcomes through the power of connected health data,”​​​ said Tal Rosenberg, president and general manager of Life Sciences, Ecosystem and Public Sector at Datavant.